Curasight

2.25 DKK

-2.17 %

Less than 1K followers

CURAS

Spotlight Stock Market

Medical Equipment & Services

Health Care

Overview

Ownership

Investor consensus

Compare

-2.17%

-28.76%

-57.5%

-54.23%

-65.93%

-60.74%

-67.24%

-83.88%

Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer. Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.

Market cap

161.26M DKK

Turnover

2.15K DKK

Revenue

EBIT %

P/E

Dividend yield-%

Coverage

Disclaimer

Claus Thestrup

CEO, Sweden

Latest research

Latest analysis report

Released: 07.05.2025

Financial calendar

28.5

2025

General meeting '25

28.8

2025

Interim report Q2'25

27.11

2025

Interim report Q3'25

All

Research

Webcasts

Press releases

ShowingAll content types

Dagens aktienyheder 14/05: Wirtek A/S, GrønlandsBANKEN, Rovsing A/S og Curasight

Analyst Commentyesterday by

Jesper Thomsen

Dagens aktienyheder 14/05: Wirtek A/S, GrønlandsBANKEN, Rovsing A/S og Curasight

Dagens aktienyheder med Wirtek A/S, GrønlandsBANKEN, Rovsing A/S og Curasight

Wirtek Grønlandsbanken Rovsing Curasight

Curasight - Video med opfølgning på kapitalforhøjelsen DKK 100 mio.

Analyst Commentyesterday by

Claus Thestrup

Curasight - Video med opfølgning på kapitalforhøjelsen DKK 100 mio.

Curasight

Regulatory press releaseyesterday

Curasight: Notice of Annual General Meeting 2025

Curasight

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Create account

Webcastyesterday

Curasight – Opfølgning på fortegningsemission

Tirsdag d. 13. maj kl. 14.00 vil Curasights CEO Ulrich Krasilnikoff og CSO Andreas Kjær gennemgå fortegningsemissionen, der løber i perioden fra 2. maj til 16 maj 2025. Fokus vil være på tegningsvilkårene, hvad skal beløbet anvendes til. Derudover vil ledelsen opdatere investorerne på den seneste udvikling i første kvartal samt eventuelle nyheder omkring pipelinen.

Curasight

Regulatory press release5/13/2025, 6:46 AM

Last day of the subscription period in Curasight's rights issue of shares

Curasight

Analyst Comment5/7/2025, 7:05 AM by

Jesper Thomsen

Dagens aktienyheder 07/05: Sampo plc, Agillic, GomSpace og Curasight

Dagens aktienyheder med Sampo plc, Agillic, GomSpace og Curasight

Sampo Agillic GomSpace Group Curasight

Regulatory press release5/7/2025, 6:06 AM

Curasight A/S selects CRO to run Phase 1 trial with uTREAT[®] in brain cancer

Curasight

Research5/7/2025, 6:02 AM by

Philip Coombes, Claus Thestrup

Curasight (One-pager): Funding of pipeline

Curasight

Press release5/6/2025, 12:28 PM

BioStock: Curasight's rights issue subscription period has commenced

Curasight

Analyst Comment5/5/2025, 7:16 AM

Dagens aktienyheder 05/05: Danske Bank, Curasight og Netcompany

Dagens aktienyheder med Danske Bank, Curasight og Netcompany

Danske Bank Netcompany Group Curasight

Curasight: Video med præsentation af fortegningsemissionen

Analyst Comment5/5/2025, 6:50 AM by

Claus Thestrup

Curasight: Video med præsentation af fortegningsemissionen

Curasight

Webcast5/2/2025, 11:00 AM

Curasight – Præsentation af fortegningsemission

Fredag den 2. maj kl 13:00 vil Curasights CEO Ulrich Krasilnikoff og CSO Andreas Kjær gennemgå fortegningsemissionen, der løber i perioden fra 2. maj til 16 maj 2025. Fokus vil være på tegningsvilkårene og hvad skal beløbet anvendes til. Derudover vil ledelsen opdatere investorerne på den seneste udvikling i første kvartal samt eventuelle nyheder omkring pipelinen.

Curasight